Fennec Pharmaceuticals logo
Fennec Pharmaceuticals
FENC | NASDAQ
Chart Builder DCF Calculator
$12.76
+$1.14 (+9.81%)
At close: Nov 16, 2026, 4:00 PM ET
$12.70
-$0.06 (-0.47%)
After-hours: Nov 16, 2026, 7:30 PM ET

Fennec Pharmaceuticals Company Profile

Company profile explained

Company Profile

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated in Research Triangle Park, North Carolina.

Key Executives

Name Position
Jeffrey S. Hackman Chief Executive Officer & Director
Robert C. Andrade Chief Financial Officer
Christiana Cioffi Chief Strategy Officer
Lei Fang President of Pharstat Inc
Mark Gowland Controller
Pierre S. Sayad Chief Medical Officer
Terry Evans Chief Commercial Officer

Latest SEC Filings

Date Type Title
Oct 19, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Oct 13, 2026 4 Filing
Oct 13, 2026 4 Filing
Oct 13, 2026 4 Filing
Oct 13, 2026 4 Filing
Oct 13, 2026 4 Filing
Oct 01, 2026 4 Filing
Oct 01, 2026 4 Filing
Oct 01, 2026 4 Filing
Oct 01, 2026 4 Filing
View All SEC Filings ➞
Fennec Pharmaceuticals
Fennec Pharmaceuticals logo
Country United States
IPO Date Sep 15, 2017
Industry Biotechnology
Sector Healthcare
Employees 35
CEO Jeffrey S. Hackman

Contact Details

68 TW Alexander Drive Research Triangle Park, North Carolina 27709 United States

Stock Details

Ticker Symbol FENC
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001211583
CUSIP Number 31447P100
ISIN Number CA31447P1009
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.